Nisa Investment Advisors LLC boosted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 313.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 331,005 shares of the company's stock after purchasing an additional 250,958 shares during the quarter. Nisa Investment Advisors LLC's holdings in Kenvue were worth $7,127,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of KVUE. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kenvue by 51.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 299,069 shares of the company's stock valued at $6,439,000 after buying an additional 102,150 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in Kenvue by 50.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 1,643,469 shares of the company's stock worth $34,677,000 after acquiring an additional 548,318 shares during the period. Stratos Wealth Partners LTD. raised its holdings in Kenvue by 7.6% in the 4th quarter. Stratos Wealth Partners LTD. now owns 52,587 shares of the company's stock valued at $1,132,000 after acquiring an additional 3,699 shares in the last quarter. Alpine Woods Capital Investors LLC lifted its position in shares of Kenvue by 0.6% during the 4th quarter. Alpine Woods Capital Investors LLC now owns 296,934 shares of the company's stock valued at $6,393,000 after acquiring an additional 1,728 shares during the period. Finally, Fulton Bank N.A. acquired a new stake in shares of Kenvue during the 4th quarter worth $1,318,000. Institutional investors own 97.64% of the company's stock.
Kenvue Stock Performance
Kenvue stock traded down $0.12 during trading hours on Wednesday, hitting $20.23. The stock had a trading volume of 11,806,451 shares, compared to its average volume of 16,856,621. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The business's 50 day simple moving average is $19.98 and its 200-day simple moving average is $20.21. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. The company's revenue for the quarter was down 2.7% on a year-over-year basis. On average, research analysts predict that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were issued a $0.20 dividend. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a yield of 3.95%.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on KVUE shares. Royal Bank of Canada dropped their price target on Kenvue from $25.00 to $24.00 and set an "outperform" rating for the company in a research note on Friday, February 9th. William Blair started coverage on shares of Kenvue in a report on Wednesday, April 3rd. They set a "market perform" rating for the company. The Goldman Sachs Group began coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a "neutral" rating and a $20.00 price objective on the stock. UBS Group upped their target price on Kenvue from $20.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, December 19th. Finally, JPMorgan Chase & Co. decreased their price target on Kenvue from $25.00 to $24.00 and set an "overweight" rating on the stock in a research note on Friday, February 9th. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $25.42.
Check Out Our Latest Analysis on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
